Back to Search
Start Over
Chronic Kidney Disease in Patients After Allogeneic Hematopoietic Cell Transplant.
- Source :
-
Transplantation Proceedings . May2022, Vol. 54 Issue 4, p1137-1140. 4p. - Publication Year :
- 2022
-
Abstract
- • Kidney damage remains significant complication of hematopoietic cell transplant affecting the mortality of transplant recipients. • Chronic graft-vs-host disease is common, and serious complication of allogeneic hematopoietic cell transplant occurs in about 60% to 80% of patients. • A total of 30% to 60% of patients with acute graft-vs-host disease progressed to chronic disease, with about 20% requiring lifelong immunosuppressive therapy that had toxic effects on kidney function. • It is very important to consider a comprehensive approach to develop and update treatment regimens and constantly monitor drug levels. Hematopoietic stem cell transplant (HSCT) is used in advanced hematologic diseases to restart the immune system. Kidney damage remains significant complication of hematopoietic cell transplant (HCT) affecting the mortality of transplant recipients. The aim of the study was to assess the advancement of chronic kidney disease (CKD) in patients after HSCT. We studied 150 patients who underwent allo-HSCT treatment in our center in years 1995 to 2020 because of acute myeloid leukemia in 47% of patients, acute lymphoblastic leukemia in 19%, and lymphoma in 32%. The mean age of patients with acute leukemia is 48 years (including acute myeloid leukemia it is 47 years, and including acute lymphoblastic leukemia it is 32 years). The mean age of lymphoma patients is 34 years. We studied the prevalence and stages of CKD. CKD stage 3a and 3b was found in 24.6%. None of the patients studied had CKD stage 4 or 5. In patients after HSCT because of both acute myeloid leukemia and acute lymphoblastic leukemia, CKD stage 3a was found in 19% and stage 3b in 7.3%. Estimated glomerular filtration rate (eGFR) >90 mL/min/1.73 m2, was found in 36.8% of this population, whereas eGFR between 90 and 60 mL/min/1.73 m2 was observed in 36.8%. In patients with lymphoma who underwent HSCT, CKD stage 3a was found in 18%, while CKD stage 3b was diagnosed in 27% of the patients. An eGFR >90 mL/min/1.73 m2, was found in 27% of this population, whereas eGFR between 90 and 60 mL/min/1.73 m2 was observed in 27% of patients. The categorization of patients according to the underlying disease is important because other drugs are used in therapy of conditioning before HCT. CKD in patients after allogeneic HSCT is common, although advanced stages were not observed, probably because the age of the population studied was not advanced. CKD in these vulnerable patients may be because of prior chemotherapy, conditioning regimen, post-HSCT calcineurin therapy, and other possible nephrotoxic drugs. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00411345
- Volume :
- 54
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Transplantation Proceedings
- Publication Type :
- Academic Journal
- Accession number :
- 158422981
- Full Text :
- https://doi.org/10.1016/j.transproceed.2022.01.020